- Patients who have not received and progressed through an immune checkpoint inhibitor unless they are medically ineligible to do so, such as due to a prior history of pneumonitis, nephritis or an autoimmune disease. Such patients receiving checkpoint inhibitor therapy must have been assessed for tumor response no earlier than after 12 weeks of therapy in order to rule out pseudoprogression.